CA209-7DX

Prostate - CA209-7DX

CA209-7DX

Objective

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant prostate cancer

Principal Investigator(s)
Hugo Hool, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials